You are here

  • Home
  • Archive
  • Volume 1, Issue Suppl 1
  • Allogeneic dendritic cell (DC) vaccination as an “off the shelf” treatment to prevent or delay relapse in elderly acute myeloid leukemia patients: results of Phase I/IIa safety and feasibility study

Citation Tools

Article menu

Download PDFPDF

Poster Presentation
Allogeneic dendritic cell (DC) vaccination as an “off the shelf” treatment to prevent or delay relapse in elderly acute myeloid leukemia patients: results of Phase I/IIa safety and feasibility study
Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
de Gruijl T, Santegoeds S, van Wetering S, et al
Allogeneic dendritic cell (DC) vaccination as an “off the shelf” treatment to prevent or delay relapse in elderly acute myeloid leukemia patients: results of Phase I/IIa safety and feasibility study
Journal for ImmunoTherapy of Cancer 2013;1:P205. doi: 10.1186/2051-1426-1-S1-P205